Why Is T4 Not Converting to T3?

T4 fails to convert adequately to T3 when something disrupts the deiodinase enzymes responsible for that conversion, or when the body actively suppresses the process in response to illness, nutrient shortfalls, medications, or metabolic stress. Your thyroid gland produces mostly T4, which is relatively inactive until enzymes strip away an iodine atom to create T3, the form that actually drives your metabolism. When those enzymes are starved of the right cofactors, inhibited by drugs, overwhelmed by inflammation, or genetically less efficient, T3 levels drop even though T4 levels look normal on blood work. This mismatch is surprisingly common and can leave you feeling hypothyroid despite lab results that seem fine on paper.

How T4 Becomes T3 in the First Place

Three enzymes handle the job of activating and deactivating thyroid hormones. Two of them, known as type 1 and type 2 deiodinase (often shortened to D1 and D2), convert T4 into T3. The third, type 3 deiodinase (D3), does the opposite: it breaks down both T4 and T3 into inactive byproducts, making it the body’s main thyroid hormone inactivator.¹ These three enzymes differ in where they sit in the body and how they behave. D1 is concentrated in the liver and kidneys. D2 is more active in the brain, pituitary gland, and skeletal muscle. D3 tends to show up wherever the body needs to protect tissues from too much thyroid hormone.²

This distributed system means conversion does not happen in one central location. Different organs regulate their own local T3 supply, which is why a blood test measuring total T3 might not capture what is happening inside a particular tissue. It also means that anything affecting the liver, the brain, or the enzymes themselves can shift the balance between activation and inactivation.

Thyroid hormones do their work inside cells, not floating in the bloodstream. Getting T4 and T3 into cells requires dedicated transporter proteins embedded in cell membranes.³ In the brain, two transporters called MCT8 and OATP1C1 ferry thyroid hormones across the blood-brain barrier.⁴ If these transporters malfunction, even adequate T3 production elsewhere in the body will not guarantee that enough reaches sensitive tissues. This is an underappreciated layer of the problem: conversion can be fine in total, yet still fall short where it matters most.

Selenium and Zinc Deficiency

The deiodinase enzymes that convert T4 to T3 are selenoproteins, meaning they need selenium built into their structure to function properly. In 1991, researchers identified that the gene for type 1 deiodinase contains a codon for the amino acid selenocysteine, and without adequate selenium, the enzyme loses much of its activity.⁵ This discovery established a direct mechanistic link between selenium status and thyroid hormone conversion. Animal research has confirmed the effect: selenium-deficient chickens showed reduced conversion of T4 to T3, along with lower levels of D1, D2, and D3.⁶

Human data paints a similar picture, though researchers note the clinical significance is still debated. Patients with selenium deficiency tend to show a high free T4-to-T3 ratio, suggesting T4 builds up because it is not being converted efficiently.⁷ Severe selenium deficiency is uncommon in well-nourished populations, but marginal deficiency is possible in people who eat limited diets, live in selenium-poor soil regions, or have gastrointestinal conditions that impair absorption.

Zinc plays a supporting role. In animal studies, zinc deficiency reduced T3 concentrations by roughly 30 percent compared to zinc-adequate controls, without changing T4 levels. The activity of hepatic type 1 deiodinase dropped by about two-thirds in zinc-deficient animals, even more steeply than the roughly 47 percent drop seen with selenium deficiency alone.⁸ These findings suggest that if you are investigating poor T4-to-T3 conversion, checking mineral status for both selenium and zinc is reasonable, particularly if you have risk factors for deficiency.

The Role of Diet and Caloric Restriction

Your body treats low energy intake as a signal to slow down metabolism, and one way it does this is by reducing T4-to-T3 conversion. This is a protective mechanism: when calories are scarce, your system conserves energy by making less of the hormone that drives metabolic rate. Very low-calorie diets, prolonged fasting, and severe carbohydrate restriction can all trigger this response.

A randomized crossover trial comparing a ketogenic diet to a high-carbohydrate, low-fat diet in healthy participants found that T3 dropped significantly during the ketogenic phase, while T4 actually rose. The T3-to-T4 ratio, a marker of conversion efficiency, did not change from baseline on the ketogenic diet but increased significantly on the high-carbohydrate diet.⁹ Thyroid-stimulating hormone (TSH) did not change on either diet, so a standard TSH test would not have flagged anything. This pattern, where T4 is normal or even elevated, TSH is fine, and T3 is low, is exactly what poor conversion looks like on lab work.

The takeaway is not that ketogenic diets are inherently harmful to the thyroid. The T3 drop may reflect a metabolic adaptation rather than a pathological state. But if you are already on thyroid medication and your symptoms worsen after a major dietary shift, reduced conversion is a plausible explanation worth discussing with your doctor.

Liver Disease and Organ Damage

The liver is a major site of T4-to-T3 conversion because it contains high concentrations of type 1 deiodinase. When the liver is damaged, that conversion capacity drops. In patients with cirrhosis, inflammation and fibrosis inhibit D1 activity, leading to lower T3 levels even when T4 remains in the normal range.¹⁰ Research dating back decades has shown that the severity of T3 reduction tracks with the degree of liver damage: the worse the cirrhosis, the lower the T3.¹¹

This creates a state that some researchers have described as resembling subclinical hypothyroidism, not because the thyroid gland itself is failing but because the liver can no longer produce enough T3 from the T4 it receives. If you have chronic liver disease and experience fatigue, cold intolerance, or other symptoms suggestive of low thyroid function, poor peripheral conversion is a strong possibility. The kidney also contributes to conversion, so significant kidney disease can produce a similar pattern, though the liver’s role is larger.

Inflammation and the Euthyroid Sick Syndrome

Serious illness, whether it is sepsis, major surgery, a heart attack, or a severe infection, commonly drives T3 levels down while T4 stays roughly normal. This pattern is called euthyroid sick syndrome (also known as non-thyroidal illness syndrome). The thyroid gland itself is healthy, but the conversion machinery is suppressed by the body’s inflammatory response.

Pro-inflammatory signaling molecules appear to disrupt deiodinase activity in a tissue-specific way. During inflammation, pathways like NF-kB compete for the cofactors that D1 needs, reducing its activity in the liver while simultaneously increasing D2 activity in the brain’s hypothalamus.12 The net effect is less T3 production in the periphery. Whether this is a protective adaptation (reducing metabolic demand during crisis) or a harmful side effect of inflammation remains an open question in endocrinology. In most cases, T3 levels recover as the acute illness resolves, and treating the low T3 directly with thyroid hormone replacement during critical illness has not shown consistent benefits in clinical trials.

A case-control study of cardiovascular patients found that about 38 percent had reduced T3 levels, and 39 percent had elevated cortisol. The cardiovascular patients had significantly higher cortisol compared to controls.¹³ Cortisol and inflammation often travel together, making it hard to isolate which is doing more damage to conversion. But the clinical picture is clear: if you are under severe physiological stress, your T3 is likely to take a hit regardless of whether your thyroid gland is functioning normally.

Medications That Block Conversion

Several widely used drugs interfere directly with T4-to-T3 conversion. The best-documented culprits include amiodarone (a heart rhythm medication), propylthiouracil (used to treat hyperthyroidism), beta-blockers like propranolol, and certain iodinated contrast agents used in imaging.¹⁴ The typical lab pattern with these drugs is a drop in T3 alongside a rise in reverse T3, which is the inactive mirror-image form that the body produces instead of active T3 when the normal conversion pathway is blocked.

Corticosteroids such as dexamethasone also depress conversion. Animal research has demonstrated that dexamethasone substantially reduces the liver’s T4-to-T3 converting activity.¹⁵ For people on long-term corticosteroid therapy, whether for autoimmune conditions, inflammatory bowel disease, or transplant rejection, this is worth knowing. If thyroid symptoms appear or worsen, the medication itself might be part of the reason.

Amiodarone deserves special attention because it is loaded with iodine and has a very long half-life, meaning its effects on thyroid metabolism can persist for months after stopping the drug. People on amiodarone need regular thyroid monitoring, and both hyperthyroidism and hypothyroidism-like effects can appear.

Genetic Variation in the Deiodinase Enzymes

Not everyone’s conversion enzymes work equally well. A common genetic variant in the gene coding for type 2 deiodinase, known as the Thr92Ala polymorphism (DIO2), has been linked to reduced T3 production. In patients who had their thyroid glands surgically removed and were placed on standard T4-only replacement therapy, those carrying one or two copies of this variant had significantly lower free T3 levels compared to patients with the normal version of the gene.¹⁶ Patients with the normal gene maintained similar T3 levels after surgery, while carriers of the variant saw a measurable drop.¹⁷

Mouse studies have helped explain why. Animals engineered with the Ala92 variant developed signs of cellular stress in the endoplasmic reticulum, which is the part of the cell where proteins are folded and processed. The altered enzyme got stuck in the wrong part of the cell and produced less T3. These mice showed hypothyroid-like symptoms in specific brain regions: they were less physically active, slept more, and took longer to memorize objects. Importantly, giving them T3 directly improved cognition, while the standard T4 replacement did not fully correct the problem.¹⁸

This polymorphism is not rare. It may partly explain why a subset of hypothyroid patients taking T4-only medication continue to feel unwell despite “normal” lab results. Their blood levels of T3 may look adequate in total, but local T3 production in the brain or other tissues could be impaired. Genetic testing for this variant is available but not yet routine in clinical practice, and guidelines have not caught up to the point of recommending different treatment based on DIO2 genotype alone.

Does Combination T4/T3 Therapy Help?

Given all the ways conversion can fail, the logical question is whether adding T3 directly to thyroid hormone replacement would solve the problem. The answer, frustratingly, is that the evidence is mixed. A systematic review of trials comparing combination T4/T3 therapy to T4-only therapy found no clear advantage of the combination in alleviating persistent symptoms of hypothyroidism, regardless of the underlying cause.¹⁹

A separate meta-analysis did find that combination therapy significantly raised total T3 levels while lowering free T4 and total T4, which makes pharmacological sense. It also found better scores on a general health questionnaire in the combination group. But there was no meaningful difference in TSH, heart rate, cholesterol, or depression scores between the two approaches, and heterogeneity across studies was moderate to high.²⁰ The disconnect between “T3 went up” and “symptoms did not consistently improve” suggests either that the trials were not well-targeted to the patients who would benefit most, or that the symptom picture is more complicated than just low T3.

One possibility is that combination therapy helps a specific subset of patients, perhaps those carrying the DIO2 polymorphism, but this benefit gets washed out in trials that include everyone with hypothyroidism. That hypothesis is reasonable given the genetics discussed above, but it has not been confirmed in large, well-designed trials stratified by genotype. Some endocrinologists prescribe combination therapy on a trial basis for patients who remain symptomatic despite optimized T4 levels, but this practice is controversial and not endorsed by most major guidelines.

Reverse T3 and What It Actually Tells You

Reverse T3 (rT3) is an inactive form of thyroid hormone produced when the body converts T4 down a different pathway. Some practitioners use rT3 as a marker of poor conversion, reasoning that if T4 is being shunted toward rT3 instead of active T3, something is wrong. The reality is more nuanced. A study of patients with hypothyroidism on different types of thyroid hormone replacement found that about 21 percent of patients taking T4 alone had elevated rT3, compared to 9 percent of patients not on any thyroid replacement.²¹ Reverse T3 correlated with free T4 levels, meaning higher T4 doses predictably produced more rT3.

This makes sense physiologically: the more T4 you put into the system, the more comes out as rT3, especially if the activating pathway is sluggish. But elevated rT3 does not necessarily mean you need treatment changes. It can simply reflect adequate or excessive T4 dosing, acute illness, caloric restriction, or normal physiological variation. Some integrative and functional medicine practitioners place heavy emphasis on the rT3-to-T3 ratio as a treatment target, but mainstream endocrinology considers rT3 testing of limited clinical utility. The controversy persists because neither side has definitive trial data to settle it.

Aging and T4-to-T3 Conversion

Conversion efficiency is not static across a lifetime. Animal research has tracked deiodinase activity from birth through old age and found a clear arc. In rats, conversion rates in the liver and kidney are very low in the first days of life, rise sharply around weaning, peak in young adulthood, and then gradually decline with age.²² There is a particularly steep drop around sexual maturation, followed by a slower, steady decline.

In humans, the picture is complicated by all the other variables that accumulate with age: more medications, more chronic disease, and changes in nutritional status. But the underlying biology suggests that aging itself contributes to less efficient conversion, which could compound the effects of anything else on this list. Older adults who feel progressively more hypothyroid despite stable TSH and T4 levels may be experiencing age-related decline in peripheral conversion.

Environmental Disruptors and the Gut

Pesticides and other environmental chemicals can interfere with thyroid hormone homeostasis at multiple points, including production, transport, and liver metabolism.²³ The research in this area is still maturing, and it is difficult to pin specific conversion problems on individual chemical exposures in everyday life. But the general principle is established: the chemical environment your body operates in affects how efficiently it handles thyroid hormones.

The gut microbiome adds another layer of complexity. Microbial metabolites including short-chain fatty acids and bile acids are increasingly recognized as modulators of thyroid hormone metabolism and the enterohepatic circulation that recycles thyroid hormones through the liver and intestines.²⁴ Dysbiosis, chronic gut inflammation, and conditions like celiac disease or inflammatory bowel disease could theoretically impair conversion indirectly by altering nutrient absorption, increasing systemic inflammation, or disrupting bile acid signaling. This is an area where the science is early-stage but the clinical implications could be significant.

Cold Exposure and Conversion on Demand

The body can also upregulate T4-to-T3 conversion when it needs more heat. Chronic cold exposure has been shown to increase conversion of T4 to T3 in rabbits, leveraging T3’s stronger effect on metabolic heat production.²⁵ In mice, acute cold exposure rapidly boosts deiodinase activity in brown adipose tissue, the specialized fat that generates heat.²⁶ This is a reminder that conversion is not just a passive, fixed-rate process. It is dynamically regulated in response to the body’s immediate needs.

The flip side of this is relevant: in obese mice, the normal cold-induced spike in deiodinase activity was blunted. If obesity impairs the ability to ramp up conversion on demand, it could contribute to the sluggish metabolic profile many people with obesity experience, and it adds another mechanism by which excess weight and thyroid function interact in ways that standard blood work will not capture.